Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125655691 | 12565569 | 1 | I | 20160524 | 20160707 | 20160718 | 20160718 | EXP | FR-NOVOPROD-500534 | NOVO NORDISK | 55.00 | YR | A | F | Y | 0.00000 | 20160718 | OT | FR | FR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125655691 | 12565569 | 1 | PS | ISOPHANE INSULIN | INSULIN NOS | 1 | Subcutaneous | 8 IU, QD | 40 | IU | UNKNOWN | 19959 | 8 | IU | SUSPENSION FOR INJECTION | QD | |||
125655691 | 12565569 | 2 | SS | NOVORAPID | INSULIN ASPART | 1 | Subcutaneous | UNK | UNKNOWN | 0 | SOLUTION FOR INJECTION | ||||||||
125655691 | 12565569 | 3 | SS | BISOCE | BISOPROLOL | 1 | Oral | 1.5 DF, QD | 16 | DF | UNKNOWN | 0 | 1.5 | DF | QD | ||||
125655691 | 12565569 | 4 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 13.50 DF, QD | 512.513001 | DF | UNKNOWN | 0 | 13.5 | DF | QD | ||||
125655691 | 12565569 | 5 | SS | CUBICIN | DAPTOMYCIN | 1 | Intravenous (not otherwise specified) | 500 MG | UNKNOWN | 0 | |||||||||
125655691 | 12565569 | 6 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Unknown | 5 ML, QD | UNKNOWN | 0 | 5 | ML | QD | ||||||
125655691 | 12565569 | 7 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Intravenous (not otherwise specified) | 40 MG, QD | UNKNWON | 0 | 40 | MG | QD | ||||||
125655691 | 12565569 | 8 | SS | PHLOROGLUCINOL W/TRIMETHYLPHLOROGLUCINOL | PHLOROGLUCINOL1,3,5-TRIMETHOXYBENZENE | 1 | Intravenous (not otherwise specified) | 1 DF, QD | UNKNOWN | 0 | 1 | DF | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125655691 | 12565569 | 1 | Type 2 diabetes mellitus |
125655691 | 12565569 | 2 | Type 2 diabetes mellitus |
125655691 | 12565569 | 3 | Product used for unknown indication |
125655691 | 12565569 | 4 | Pneumocystis jirovecii pneumonia |
125655691 | 12565569 | 5 | Bacterial infection |
125655691 | 12565569 | 6 | Acquired immunodeficiency syndrome |
125655691 | 12565569 | 7 | Oesophagitis |
125655691 | 12565569 | 8 | Acquired immunodeficiency syndrome |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125655691 | 12565569 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125655691 | 12565569 | Acute kidney injury | |
125655691 | 12565569 | Pancytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125655691 | 12565569 | 1 | 20160516 | 20160521 | 0 | |
125655691 | 12565569 | 3 | 20160513 | 20160524 | 0 | |
125655691 | 12565569 | 4 | 20160416 | 20160525 | 0 | |
125655691 | 12565569 | 5 | 20160512 | 20160528 | 0 | |
125655691 | 12565569 | 6 | 20160513 | 0 | ||
125655691 | 12565569 | 7 | 20160511 | 0 | ||
125655691 | 12565569 | 8 | 20160511 | 0 |